A significant block trade of Gland Pharma shares took place on the National Stock Exchange (NSE) on Tuesday, coinciding with the company's announcement of robust first-quarter results.

Block Trade Details

Approximately 455,110 shares of Gland Pharma changed hands in a block deal valued at ₹91.12 crore. The transaction was executed at ₹2,002.20 per share, representing a substantial institutional interest in the pharmaceutical company's stock.

Q1 Financial Highlights

The block trade comes on the heels of Gland Pharma's impressive financial performance for the quarter ended June 30:

• Revenue from operations increased by 7% year-on-year to ₹15,056.00 million
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) surged by 39% to ₹3,678.00 million
• EBITDA margin improved significantly to 24%, up from 19% in the same quarter last year
• Profit After Tax (PAT) showed a remarkable 50% growth, reaching ₹2,155.00 million
• PAT margin expanded to 14%, compared to 10% in the previous year's corresponding quarter

Operational Performance

Gland Pharma's base business, excluding its Cenexi operations, demonstrated solid growth:

• Base business revenue grew by 3% year-on-year to ₹10,409.00 million
• EBITDA for the base business increased by 22% to ₹3,592.00 million
• EBITDA margin for the base business improved to 35%, up from 29% in the same quarter last year

Geographic Performance

The company reported mixed results across different markets:

Management Commentary

Srinivas Sadu, Executive Chairman of Gland Pharma, commented on the results: "We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships."

Shyamakant Giri, Chief Executive Officer, added: "This quarter's performance, with improved margins and Cenexi achieving EBITDA break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth."

Business Highlights

• R&D expenses for the quarter were ₹460.00 million, representing 4.4% of revenue
• The company launched 12 new molecules in regulated markets during the quarter
• One ANDA was filed and nine were approved, bringing the total to 372 ANDA filings in the U.S. (325 approved, 47 pending)
• Gland Pharma is expanding its GLP-1/Pen/cartridge capacity from ~40 million to 140 million units

The block trade, coupled with Gland Pharma's strong quarterly performance, underscores investor confidence in the company's growth trajectory and operational efficiency improvements.

Gland Pharma , a leading injectable-focused pharmaceutical company, has announced strong financial results for the first quarter. The company reported a significant 50% year-on-year increase in Profit After Tax (PAT) and achieved EBITDA breakeven for its Cenexi operations.

Financial Highlights

• Revenue from operations grew by 7% year-on-year to ₹15,056.00 million
• EBITDA increased by 39% year-on-year to ₹3,678.00 million
• EBITDA margin expanded by 549 basis points to 24%
• PAT surged by 50% year-on-year to ₹2,155.00 million
• PAT margin improved by 405 basis points to 14%

Operational Performance

The company's base business (Gland) showed steady growth with a 3% year-on-year increase in revenue to ₹10,409.00 million. The EBITDA for this segment rose by 22% to ₹3,592.00 million, with the EBITDA margin expanding to 35%.

Cenexi, Gland Pharma's European subsidiary, achieved a significant milestone by reaching EBITDA breakeven this quarter. The segment reported revenue of €48 million (₹4,648.00 million), marking a 20% year-on-year growth.

Geographic Performance

R&D and Product Pipeline

Gland Pharma continued to invest in research and development, with R&D expenses of ₹460.00 million, representing 4.4% of revenue. The company made significant progress in its product pipeline:

• Launched 12 new molecules in regulated markets
• Filed one ANDA and received approval for nine in the quarter
• Cumulative ANDA filings in the U.S. reached 372, with 325 approved and 47 pending
• Advanced its complex injectables pipeline with six products already launched and three more in line for approval

Strategic Initiatives

The company is focusing on several key areas for growth:

1. GLP-1 Expansion: Launched Liraglutide in the UK and Australia, with plans to increase GLP-1/Pen/cartridge capacity from 40 million to 140 million units.

2. Ready-to-Use (RTU) Bags: Filed one RTU infusion bag, bringing the total to 20 RTU products filed in the USA (14 approved). Ten additional products are under development.

3. Co-development Partnerships: 15 products are in co-development, with commercialization expected to begin in FY28.

4. Cenexi Integration: Streamlining operations and optimizing costs at the European facilities, with new product transfers and capacity expansions underway.

Management Commentary

Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, "We're off to a positive start this year with growth in revenue and a significant jump in profitability, driven by strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing as we strengthen our capabilities, add new capacity, and boost R&D with complex products and key partnerships."

Mr. Shyamakant Giri, Chief Executive Officer, added, "This quarter's performance, with improved margins and Cenexi achieving EBITDA breakeven, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth."

Gland Pharma's strong quarterly results demonstrate the company's resilience and strategic focus on high-value injectables and geographic expansion. With ongoing investments in R&D, manufacturing capabilities, and strategic partnerships, the company appears well-positioned for continued growth in the global pharmaceutical market.